Oberg K - Search Results

1

PET in the diagnosis of neuroendocrine tumors.

Sundin A, Eriksson B, Bergström M, Långström B, Oberg K, Orlefors H. Sundin A, et al. Among authors: oberg k. Ann N Y Acad Sci. 2004 Apr;1014:246-57. doi: 10.1196/annals.1294.027. Ann N Y Acad Sci. 2004. PMID: 15153441 Review.

2

Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer.

Yu D, Leja-Jarblad J, Loskog A, Hellman P, Giandomenico V, Oberg K, Essand M. Yu D, et al. Among authors: oberg k. Neuroendocrinology. 2017;105(1):54-66. doi: 10.1159/000448430. Epub 2016 Jul 21. Neuroendocrinology. 2017. PMID: 27442441

3

Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.

Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, Salazar R, Oberg K. Toumpanakis C, et al. Among authors: oberg k. Neuroendocrinology. 2014;99(2):63-74. doi: 10.1159/000358727. Epub 2014 Jan 21. Neuroendocrinology. 2014. PMID: 24458014 Review.

4

IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug?

Amoroso V, Pavel M, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A. Amoroso V, et al. Among authors: oberg k. Future Oncol. 2018 Apr;14(10):897-899. doi: 10.2217/fon-2017-0667. Epub 2018 Mar 12. Future Oncol. 2018. PMID: 29528242 No abstract available.

5

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Caplin ME, et al. Among authors: oberg k. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646366 Review.

6

Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors.

Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, Oberg K, Eriksson B, Nyman R. Granberg D, et al. Among authors: oberg k. Acta Radiol. 2007 Mar;48(2):180-5. doi: 10.1080/02841850601080440. Acta Radiol. 2007. PMID: 17354139

7

Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.

Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B. Orlefors H, et al. Among authors: oberg k. J Clin Endocrinol Metab. 2005 Jun;90(6):3392-400. doi: 10.1210/jc.2004-1938. Epub 2005 Mar 8. J Clin Endocrinol Metab. 2005. PMID: 15755858

8

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.

Fjällskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Fjällskog ML, et al. Among authors: oberg k. Med Oncol. 2002;19(1):35-42. doi: 10.1385/MO:19:1:35. Med Oncol. 2002. PMID: 12025889

9

Established clinical use of octreotide and lanreotide in oncology.

Oberg K. Oberg K. Chemotherapy. 2001;47 Suppl 2:40-53. doi: 10.1159/000049160. Chemotherapy. 2001. PMID: 11275701 Review.

10

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.

Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K. Afargan M, et al. Among authors: oberg k. Endocrinology. 2001 Jan;142(1):477-86. doi: 10.1210/endo.142.1.7880. Endocrinology. 2001. PMID: 11145612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results